230 likes | 246 Views
MARS Bioimaging Ltd spectral CT for biomedical imaging. Anthony Butler. www.marsbioimaing.com. Overview. Founded 2008: Spin out of University of Canterbury Exclusive licence for CERN Medipix3 detector technology Own all IP relating spectral CT from the university Products:
E N D
MARS Bioimaging Ltd spectral CT for biomedical imaging Anthony Butler www.marsbioimaing.com
Overview Founded 2008: Spin out of University of Canterbury Exclusive licence for CERN Medipix3 detector technology Own all IP relating spectral CT from the university Products: MARS scanners: Medipix3 based microCT system MARS camera: Medipix3 detector and readout for integration into 3rd party CTs
Spectral CT is now possible Medipix All Resolution System Energy resolution Spatial resolution Temporal resolution MARS spectral CT Xray source Medipix Color detectors
Low GAG Cartilage Bone
MARS scanner microCT for small animal and pathology researcher
MARS Medipix3 camera Medipix3 camera system for integration into 3rd party systems Up to 8 Simultaneous energies 55µm or 110 µm pixel pitch resolution 1 to 6 Medipix chips (28x52mm array) Silicon or CdTe/CZT Excellent energy resolution ( Charge sharing compensation ) Image of PCB taken with Medipix3 Si-quad, 28x28mm
Market strategy • Get MARS systems to key opinion leader’s labs • Enable researchers using MARS tool to validate spectral CT • Provide camera units for existing pre-clinical manufacturers to integrate into their systems • Leverage pre-clinical adoption to find partner for human imaging
MARS project structure • MARS is the technology • MARS Bioimaging Ltd • aka. “MBI” • Commercial outlet for NZ’s R+D • Research teams • University of Canterbury • University of Otago
MARS project structure • MARS Bioimaging Ltd • aka. “MBI” • Commercial outlet for NZ’s R+D • Shareholders • University of Canterbury • Individual scientist • Private investors
MARS IP structure MARS Bioimaging Ltd Exclusive license for small animal and human CT All IP relating to spectral CT technology University of Canterbury Medipix3 Collaboration Sub-contract for pre-clinical research University of Otago
MARS Funding structure Investment MARS Bioimaging Ltd University of Canterbury Medipix3 Collaboration University of Otago
MARS Funding structure Sales Investment MARS Bioimaging Ltd University of Canterbury Medipix3 Collaboration University of Otago
MARS Funding structure Sales Investment MARS Bioimaging Ltd Contribution to Medipix3 development Scholarship funding University of Canterbury Medipix3 Collaboration University of Otago
MARS Funding structure Sales Investment MARS Bioimaging Ltd Contribution to Medipix3 development Scholarship funding University of Canterbury Medipix3 Collaboration NZ government funding University of Otago
Government instruction 80% of NZ government funding is aimed at economic return • Key concept is international revenue • Want a route to market early in an R+D program
Benefit to research • Provides direction and focus • Get the technology into users hands early • Provides new funding routes
Personal • Satisfaction – your research is used!!! • New challenges
Personal • Satisfaction – your research is used!!! • New challenges • Potential for financial gain… …. but I’m a radiologist!!
Summary • MARS-CT make spectral CT possible • Early adopters already purchasing www.marsbioimaging.com